0001415889-24-006475.txt : 20240304
0001415889-24-006475.hdr.sgml : 20240304
20240304212222
ACCESSION NUMBER: 0001415889-24-006475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cowan Elvia
CENTRAL INDEX KEY: 0001960048
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 24717998
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, SUITE 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
form4-03052024_020305.xml
X0508
4
2024-02-29
0001649094
Vaxcyte, Inc.
PCVX
0001960048
Cowan Elvia
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300
SAN CARLOS
CA
94070
false
true
false
false
SVP, FINANCE
1
Common Stock
2024-02-29
4
A
0
5400
0
A
13158
D
Common Stock
2024-03-01
4
M
0
11000
25.92
A
24158
D
Common Stock
2024-03-01
4
S
0
2322
73.084
D
21836
D
Common Stock
2024-03-01
4
S
0
4455
73.689
D
17381
D
Common Stock
2024-03-01
4
S
0
4901
74.9
D
12480
D
Common Stock
2024-03-02
4
F
0
324
71.55
D
12156
D
Stock Option (right to buy)
73.82
2024-02-29
4
A
0
25000
0
A
2024-02-28
Common Stock
25000
25000
D
Stock Option (right to buy)
25.92
2024-03-01
4
M
0
11000
0
D
2032-08-08
Common Stock
11000
129000
D
Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-03-04